<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Graf, Erin</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The Emergence of Pathogen Genomics in Diagnostic Laboratories</style></title><secondary-title><style face="normal" font="default" size="100%">American Society for Clinical Laboratory Science</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2019-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">67-69</style></pages><doi><style  face="normal" font="default" size="100%">10.29074/ascls.2019001776</style></doi><volume><style face="normal" font="default" size="100%">32</style></volume><issue><style face="normal" font="default" size="100%">2</style></issue><abstract><style  face="normal" font="default" size="100%">Next-generation sequencing (NGS) technologies enable one to obtain genomic information about pathogens directly from clinical samples or isolates on a scale never before possible with polymerase chain reaction or Sanger sequencing. Clinical microbiology laboratories are rapidly finding the “low-hanging fruit”–type applications for this disruptive technology as it becomes cost-effective with reasonable turn-around times. This includes the use of metagenomic NGS for pathogen detection in primary clinical samples. It also includes the use of NGS for detection of antimicrobial-resistance genes in bacteria that are difficult and/or slow to grow in culture. Finally, NGS offers improvement in resolution of viral and bacterial outbreaks and streamlines workflows for a “one-size-fits-all” protocol. There are still significant barriers to implementation that must be considered. These include workforce skills required for high-complexity wet-bench protocols and data analysis, as well as validation approaches for interpretation given the lack of US Food and Drug Administration–approved systems. Regardless, NGS will continue to be a game changer in clinical microbiology, and laboratories must be prepared to face the challenges associated with adoption of this technology.</style></abstract></record></records></xml>